Skip to content

Promore Pharma granted EU patent regarding treatment of chronic wounds

STOCKHOLM, 10 August 2022 – Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, have announced today that the company has received a granted patent in the European Union for the use of the candidate drug ropocamptide (LL-37) for the treatment of chronic wounds.

Promore Pharma’s product candidate ropocamptide is undergoing development for treatments aimed at healing venous leg ulcers. Promore Pharma announced today that they have been granted another patent by the European Patent Office (EPO) regarding its substance ropocamptide. The patent protects the treatment of chronic wounds such as venous leg ulcers and diabetic foot ulcers by treating patients with a pharmaceutical formulation containing ropocamptide in therapeutically effective doses. The patent period extends until at least November 2034, with the possibilities of further patent extension.

“We are now taking another step in our strategic work to create far-reaching intellectual property protection for our innovative prescription drug for the treatment of various types of hard-healing wounds,” said Jonas Ekblom, CEO of Promore Pharma. ” Overall, we now have strong and extensive patent protection for ropocamptide in some of the world’s largest national pharmaceutical markets, which will be of paramount importance when our product reaches the market,” he continued.


Within the ropocamptide project for the treatment of venous leg ulcers, which is the most common type of chronic leg ulcers, a clinical Phase II trial, the HEAL LL-37 study, was concluded during the autumn 2020. The most important finding from that clinical trial was that ropocamptide shows a significant effect in the patient subgroup with large wounds (≥10 cm2). The company assesses that there are at least 1 million patients in North America, the EU, the UK, and Japan with large venous leg ulcers, which implies an annual addressable market of approx. SEK 30 billion.